Drugmakers Merck & Co Inc. and Glenmark Pharmaceuticals Ltd. lost a bid to kill multidistrict litigation alleging a pay-for-delay scheme involving the cholesterol medication Zetia when a Virginia federal judge on Thursday said an arbitration clause in Merck’s contracts with customers improperly waived their statutory rights, making it unenforceable…

Read this piece in its entirety at Law360.